Eli Lilly and Co. announced it revised a contract with the US government for bamlanivimab, the drugmaker's COVID-19 antibody drug, due to concerns about its efficacy against new coronavirus variants. The modified agreement states the drug will now be sold in combination with etesevimab and cancels the remaining orders of bamlanivimab scheduled for delivery by the end of March.